glp 1 agonists long term effects Struggling with GLP-1 therapy side effects? You're not alone. This Clinician Guide: Managing Common GLP-1 Receptor Agonist Side provides practical tips on recognizing, preventing and managing gastrointestinal and nutritional side effects long term effects of glp

Food and Drug Administration (FDA) on the 1st approved 'Foundayo (ingredient name: orforglipron),' an oral obesity treatment developed by Eli Lilly, the company that supplies the obesity drug 'Mounjaro.' This is the second oral GLP-1 class obesity treatment to be approved, following the pill form of Novo Nordisk's 'Wegovy' last December

Popular medications in this category include Semaglutide and Liraglutide

The synergistic effect of poor dietary quality and lack of exercise creates a fertile ground for the development and progression of metabolic disorders

The GLP-1 based therapies were also found to be associated with significant reductions in the serum levels of total cholesterol, LDL-cholesterol and triglycerides

There are still so many misconceptions about these medications among the general public

Navigate the healthcare industry Healthcare Brew covers pharmaceutical developments, health startups, the latest tech, and how it impacts hospitals and providers to keep administrators and providers informed